Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ingenol Mebutate

FDA-approved product (gel, topical), marketed as Ingenol Mebutate, Picato.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ingenol Mebutate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other chemotherapeutics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D06BX02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ingenol Mebutate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ingenol Mebutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

    NCT02654769 · start 2015-02

    Registered record
    Registry ID
    NCT02654769
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol Mebutate (Picato®); Generic Ingenol Mebutate; Vehicle Foam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-09
    Enrolment
    441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol Mebutate (Picato®); Generic Ingenol Mebutate; Vehicle Foam
    PhasePhase 3
    Registry statusCompleted

  • Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

    NCT02354391 · start 2015-01

    Registered record
    Registry ID
    NCT02354391
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate Picato® and MAL PDT day 1, day 5; Ingenol mebutate Picato® day 2, 3, 4; MAL PDT day 5
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2019-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate Picato® and MAL PDT day 1, day 5; Ingenol mebutate Picato® day 2, 3, 4; MAL PDT day 5
    PhasePhase 2
    Registry statusUnknown

  • PMS to Evaluate the Safety and Efficacy of Picato® Gel

    NCT02421471 · start 2014-09

    Registered record
    Registry ID
    NCT02421471
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate 0.015 percent or 0.05 percent gel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-09
    Completion
    2018-01-19
    Enrolment
    1,324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate 0.015 percent or 0.05 percent gel
    PhaseNot recorded
    Registry statusCompleted

  • The Real Life Topical Field Treatment of Actinic Keratosis Study

    NCT02362152 · start 2014-07

    Registered record
    Registry ID
    NCT02362152
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate; 5-fluorouracil; Imiquimod; Diclofenac
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-07
    Completion
    2015-12
    Enrolment
    1,168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate; 5-fluorouracil; Imiquimod; Diclofenac
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis

    NCT02242747 · start 2014-05

    Registered record
    Registry ID
    NCT02242747
    Conditions
    Actinic Keratosis
    Interventions
    ingenol mebutate; 5% 5-FU
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    Interventioningenol mebutate; 5% 5-FU
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

    NCT02124239 · start 2014-04

    Registered record
    Registry ID
    NCT02124239
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-11
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate
    PhasePhase 1
    Registry statusCompleted

  • TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction

    NCT04202445 · start 2014-04

    Registered record
    Registry ID
    NCT04202445
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-02
    Enrolment
    1,218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate
    PhaseNot recorded
    Registry statusCompleted

  • Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

    NCT01926496 · start 2013-09-11

    Registered record
    Registry ID
    NCT01926496
    Conditions
    Actinic Keratosis (AK)
    Interventions
    Ingenol Mebutate Gel, 0.015%; Imiquimod Cream, 5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09-11
    Completion
    2019-07-11
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis (AK)
    InterventionIngenol Mebutate Gel, 0.015%; Imiquimod Cream, 5%
    PhasePhase 4
    Registry statusCompleted

  • Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

    NCT01892137 · start 2013-07

    Registered record
    Registry ID
    NCT01892137
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate gel 0.05%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-05
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate gel 0.05%
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

    NCT02251652 · start 2013-04

    Registered record
    Registry ID
    NCT02251652
    Conditions
    Actinic Keratoses
    Interventions
    Ingenol Mebutate; Cryotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-04
    Completion
    2015-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratoses
    InterventionIngenol Mebutate; Cryotherapy
    PhasePhase 4
    Registry statusCompleted

  • Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

    NCT01836367 · start 2013-03

    Registered record
    Registry ID
    NCT01836367
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol Mebutate 0.015%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-03
    Completion
    2013-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol Mebutate 0.015%
    PhasePhase 1
    Registry statusCompleted

  • Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

    NCT01803477 · start 2013-02

    Registered record
    Registry ID
    NCT01803477
    Conditions
    Actinic Keratosis
    Interventions
    once daily for two consecutive days (Picato)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2013-12
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    Interventiononce daily for two consecutive days (Picato)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

    NCT01600014 · start 2012-05

    Registered record
    Registry ID
    NCT01600014
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate gel, 0.015%; Vehicle gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-02
    Enrolment
    463

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate gel, 0.015%; Vehicle gel
    PhasePhase 3
    Registry statusCompleted

  • A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

    NCT01541553 · start 2012-03

    Registered record
    Registry ID
    NCT01541553
    Conditions
    Actinic Keratosis
    Interventions
    Cryotherapy; Vehicle; Ingenol metabute
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-07
    Enrolment
    367

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionCryotherapy; Vehicle; Ingenol metabute
    PhasePhase 3
    Registry statusCompleted

  • PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

    NCT01387711 · start 2011-08

    Registered record
    Registry ID
    NCT01387711
    Conditions
    Actinic Keratosis
    Interventions
    PEP005 (Ingenol mebutat Gel, 0.05 %)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionPEP005 (Ingenol mebutat Gel, 0.05 %)
    PhasePhase 1
    Registry statusCompleted